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OBJECTIVES The Early Retavase-Thrombolysis In Myocardial Infarction (ER-TIMI) 19 trial tested the
feasibility of prehospital initiation of the bolus fibrinolytic reteplase (rPA) and determined the
time saved by prehospital rPA in the setting of contemporary emergency cardiac care.
BACKGROUND Newer bolus fibrinolytics have undergone only limited evaluation for prehospital adminis-
tration. In addition, as door-to-drug times have decreased, the relevance of findings from
prior trials of prehospital fibrinolysis has become less certain.
METHODS Patients (n  315) with ST-elevation myocardial infarction (STEMI) were enrolled in 20
emergency medical systems in North America. The time from emergency medical service
(EMS) arrival to administration of a fibrinolytic was compared between study patients
receiving prehospital rPA and sequential control patients from 6 to 12 months before the
study who received a fibrinolytic in the hospital.
RESULTS Acute myocardial infarction was confirmed in 98%. The median time from EMS arrival to
initiation of rPA was 31 min (25th to 75th percentile, 24 min to 37 min). The time from
EMS arrival to in-hospital fibrinolytic for 630 control patients was 63 min (25th to 75th
percentile, 48 min to 89 min), resulting in a time saved of 32 min (p  0.0001). By 30 min
after first medical contact, 49% of study patients had received the first bolus of fibrinolytic
compared with only 5% of controls (p 0.0001). In-hospital mortality was 4.7%. Intracranial
hemorrhage occurred in 1.0%.
CONCLUSIONS Prehospital administration of rPA is a feasible approach to accelerating reperfusion in patients
with STEMI. Valuable time savings can be achieved in the setting of contemporary transport
and door-to-drug times and may translate into an improvement in clinical outcomes. (J Am
Coll Cardiol 2002;40:71–7) © 2002 by the American College of Cardiology Foundation
Given the critical relationship between the time to success-
ful reperfusion and outcomes in the treatment of patients
with acute ST-segment elevation myocardial infarction
(STEMI), the potential advantages of prehospital adminis-
tration of fibrinolytic therapy have a sound theoretical basis
(1–4). However, despite consistent evidence that prehospi-
tal fibrinolysis reduces time to treatment (5–10), and meta-
analysis of results from randomized trials that suggests
improved survival (11), a number of barriers have hindered
the widespread development of prehospital fibrinolytic pro-
grams in North America (12,13). In part, the complexity of
administering fibrinolytics that require weight-adjusted
continuous infusions may have limited their use in the field.
Moreover, as on-scene, transport and door-to-drug times
have decreased in urban and semiurban environments, the
relevance of findings from prior trials to current practice has
become uncertain.
The Early Retavase-Thrombolysis In Myocardial Infarc-
tion (ER-TIMI) 19 trial was designed to test the feasibility
of prehospital initiation of the bolus-fibrinolytic reteplase
(rPA) and to evaluate the time saved by prehospital admin-
istration of rPA in the setting of contemporary emergency
cardiac care in a diverse group of emergency medical systems
in North America.
METHODS
Study centers. Patient enrollment occurred between May
1999 and July 2001 in 20 emergency medical systems across
North America. The participating systems were located in
14 states in the U.S. and two provinces in Canada and
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included 70 hospitals and approximately 280 ambulances.
Ten systems were located in urban environments with the
remainder split between semi-urban (n  6) and rural (n 
4) environments. Ten systems were routinely performing
prehospital 12-lead electrocardiography before participating
in the trial. The protocol was approved by the relevant
emergency medical, state regulatory and institutional review
boards, and written informed consent was obtained from all
patients for the collection of data regarding the primary end
point, study drug administration and electrocardiogram
(ECG) interpretation. In all but one center, consent for
in-hospital follow-up was also obtained.
Study population. Men and women who were at least 18
years old were eligible for inclusion in the trial if they had
ischemic discomfort lasting 30 min or longer within the
prior 12 h and exhibited ST-segment elevation 0.1 mV in
two or more contiguous limb leads or 0.2 mV in two or
more contiguous precordial leads, or new left bundle branch
block on a 12-lead ECG obtained in the field.
Patients were excluded if they met any of the following
criteria:
1. Cardiovascular: cardiogenic shock or pulmonary edema
requiring intubation; symptoms suggestive of aortic dis-
section;
2. Bleeding risk: single reliable measurement of systolic
blood pressure 180 mm Hg or diastolic blood pressure
110 mm Hg at any time from initial medical contact
to enrollment; known prior history of stroke, transient
ischemic attack, intracranial neoplasm, arteriovenous
malformation or aneurysm; active bleeding or history of
bleeding diathesis; major surgery, trauma or internal
bleeding within prior four weeks;
3. Prior or concomitant therapy: oral anticoagulation in
prior three days;
4. General: suspected cocaine or amphetamine-induced
myocardial infarction (MI); known or suspected
pregnancy.
Study protocol. Initial patient care conformed to Ad-
vanced Cardiac Life Support recommendations for the
evaluation and treatment of patients with suspected MI.
Paramedical personnel obtained a brief history, and physical
examination, and evaluated the inclusion/exclusion check-
list. This information, along with a 12-lead ECG per-
formed in the field, was transmitted via cellular or landline
communications to the medical control physician who
determined the patient’s eligibility based upon review of the
inclusion/exclusion criteria and interpretation of the trans-
mitted 12-lead ECG. The protocol specified that eligible
patients be treated immediately after enrollment with
325 mg of aspirin (unless contraindicated) and 10 U of rPA
administered as an intravenous bolus over 2 min, followed
by a second bolus of 10 U of rPA 30 min later. If the
transport time to the hospital exceeded 30 min, the second
dose of rPA was administered in the ambulance. Intrave-
nous unfractionated heparin was administered with a bolus
of 60 U/kg (maximum of 4,000 U) and an initial infusion of
12 U/kg/h (maximum 800 U/h) as soon as possible after
enrollment (either in the field or hospital, depending on the
transport time).
On arrival in the emergency department, patients under-
went immediate evaluation by an emergency physician. If
fibrinolysis was determined not to be indicated, appropriate
medical therapy was undertaken without administration of
the second bolus of rPA. If deemed indicated by the treating
physician, patients could also be referred for immediate
coronary angiography without receiving the second bolus of
rPA. Use of beta-blockers, nitrates, calcium antagonists and
other medications was at the discretion of the treating
physician.
Clinical procedures. Heparin anticoagulated blood was
obtained before administration of the fibrinolytic for per-
formance of a rapid qualitative assay for cardiac troponin I,
myoglobin and the MB fraction of creatine kinase (Cardiac
STATus, Spectral Diagnostics, Frederick, Maryland). Re-
sults of the rapid assay were recorded on the case report
form for investigational use only.
Standard 12-lead ECGs were performed before enroll-
ment, upon arrival in the emergency department and 90 min
after the first bolus of rPA. All available ECGs were sent to
the TIMI ECG Core Laboratory (Boston, Massachusetts)
for quantitative ST-segment analysis. The sum of ST
deviation on the ECGs from baseline, hospital arrival and
90 min was determined using previously described methods
(14), and the percent ST resolution (STRES) from baseline
to emergency department arrival and baseline to 90 min was
calculated for all patients with both tracings available. The
STRES for each patient was categorized by two well-
described classification schemes: 1) 50% STRES versus
50% STRES, and 2) complete (70%), partial (30% to
70%) or none (30%) (14).
End points and statistical analysis. The primary end
point of the study was the amount of time saved by
prehospital administration of rPA compared with in-
hospital administration of a fibrinolytic in a control popu-
lation of consecutive patients with STEMI transported to
the hospital by ambulance and treated with a fibrinolytic in
the 6 to 12 months before initiation of ER-TIMI 19. The
control population was identified through pharmacy records
Abbreviations and Acronyms
CI  confidence interval
ECG  electrocardiogram
EMS  emergency medical service
ER-TIMI  Early Retavase-Thrombolysis In Myocardial
Infarction trial
MI  myocardial infarction
MITI  Myocardial Infarction Triage and
Intervention trial
rPA  reteplase
STEMI  ST-segment elevation myocardial infarction
STRES  ST-segment resolution
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of all patients receiving a fibrinolytic for STEMI in each of
the hospitals participating in ER-TIMI 19. The times of
emergency medical service (EMS) arrival on the scene,
ambulance arrival in the hospital and initiation of the first
bolus of fibrinolytic were obtained from the EMS run-logs
and nursing records, respectively. The time from EMS
arrival to initiation of the first bolus of a fibrinolytic was
calculated for patients treated with rPA in ER-TIMI 19
and control patients treated with a fibrinolytic initiated
in-hospital. The prospectively defined analysis of the pri-
mary end point was comparison of the time elapsed from
EMS arrival to administration of a fibrinolytic in patients
enrolled in ER-TIMI 19 versus control patients using a
nonparametric mixed-effects model, including the treatment
group as a fixed effect and the enrolling system as a random
effect. Based upon an estimated standard deviation of 91
min for the time from EMS arrival to fibrinolytic, a sample
size of 340 patients and at least as many controls was
calculated to provide 99% power to detect a difference of 30
min.
Two patients were not evaluable for the primary end
point due to missing times. One patient drove by car to a
fire station, and the time of the first interaction was not
recorded. For the second patient, the time of rPA admin-
istration was not recorded on the EMS run sheet and, thus,
no source documentation was available. Clinical event rates
were tabulated for all patients with available data who
provided consent for in-hospital follow-up through hospital
discharge or seven days. In one center, nine patients did not
provide consent for follow-up of in-hospital clinical events.
Five additional patients had missing data. The study was
not designed for comparison of clinical event rates.
RESULTS
A total of 315 patients were enrolled in the trial. Baseline
characteristics for the study population are described in
Table 1. All patients received the first bolus of rPA. Because
patients were not excluded from the study based on the
expected transport time, 14 patients received the first bolus
of rPA after arriving in the emergency department, an
average of 38 min after EMS on-scene arrival and 3.5 min
after arriving in the emergency department. A total of 14
patients were treated without administration of the second
bolus of rPA (Table 2). A diagnosis of acute MI was
confirmed by the local investigator in 98% of patients by
elevation of cardiac markers and/or evolution of diagnostic
Q waves on the ECG. Of the patients without confirmed
MI, one was classified as having ischemic heart disease
without infarction, and five were classified as “other” by the
local investigator. A rapid qualitative assay for creatine
kinase-MB, cardiac troponin I and myoglobin performed on
blood obtained in the field (n  210) a median of 79 min
after symptom onset was positive for at least one marker in
23% of cases. Myoglobin was elevated in 15.8% of cases,
cardiac troponin I in 15.9% and creatine kinase-MB in
14.4%.
The control population was comprised of 630 patients
with STEMI who had been transported by participating
EMS to study centers and treated with a fibrinolytic before
the date of initiating ER-TIMI 19 in each center. Limited
demographic data were collected for these patients, indicat-
ing a median age of 62 years (25th to 75th percentile, 53 to
73 years) and predominance of male patients (63.3%).
Time saved by prehospital rPA. Among evaluable pa-
tients (n  313), the median time from arrival of EMS to
initiation of the first bolus of rPA was 31 min with an
interquartile range of 24 to 37 min. In contrast, the time
from EMS arrival to in-hospital administration of a fibrino-
lytic for control patients was 63 min (25th to 75th percen-
tile, 48 to 89 min), resulting in a median time saved of
32 min (p  0.0001). Although there was some variation in
the time to administration of the first bolus across systems,
the impact of introducing prehospital rPA remained highly
significant (p  0.0001) after adjusting for the effect of
variability between systems. The distribution of time to
treatment for patients treated with prehospital rPA and for
historical controls is depicted in Figure 1. By 30 min after
first medical contact, 49% of patients in ER-TIMI 19 had
received the initial bolus of rPA compared with only 5% of
control patients (p  0.0001). At 1 h after EMS arrival,
97% of patients enrolled in ER-TIMI 19 had received the
Table 1. Baseline Characteristics for Patients Treated With
Prehospital Reteplase
Age, yrs 60 (50–71)
Men 74.5%
Weight, kg 82 (71–91)
Hypertension 47.7%
Diabetes 16.8%
Hypercholesterolemia 30.5%
Prior MI 11.8%
Prior CABG 4.6%
Prior PCI 8.9%
History of CHF 3.6%
Systolic BP, mm Hg 132 (112–150)
Heart rate, beats/min 72 (60–88)
Anterior MI or LBBB 38%*
Data for continuous variables are reported as the median and 25th to 75th percentiles.
Categorical variables are reported as a proportion. *Interpreted in electrocardiogram
core laboratory (n  286).
BP  blood pressure; CABG  coronary artery bypass grafting; CHF 
congestive heart failure; LBBB  left bundle branch block; MI  myocardial
infarction; PCI  percutaneous coronary intervention.
Table 2. Reasons for Not Administering Second Bolus
of Reteplase
Number
Received 2nd bolus 301 (96%)
No second bolus 14 (4%)
Referral for immediate catheterization 4
Cardiac arrest 3
Diagnosis other than MI 1
Nondiagnostic ECG 1
Severe hypertension 1
Other/missing 4
ECG  electrocardiogram; MI  myocardial infarction.
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first bolus of rPA, whereas, reperfusion therapy had been
initiated for less than half of the control population (p 
0.0001). The total time from EMS arrival on the scene to
arrival in the emergency department, termed the “field
management interval” (15), was prolonged by 14 min for
patients treated with prehospital rPA compared with con-
trols (42 vs. 28 min).
The impact of introducing a prehospital fibrinolytic
program was evaluated in the context of historical perfor-
mance of each system with respect to field management and
door-to-drug times. The median door-to-drug time before
introducing prehospital rPA was 32 min, consistent with
the contemporary U.S. national average (16). When
grouped by their prior performance with respect to door-
to-drug times for in-hospital fibrinolysis, systems with
door-to-drug times exceeding 20 min were found to achieve
a significant reduction in the time to reperfusion therapy
after the introduction of prehospital rPA (median time
saved: 30 min for systems with historical door-to-drug times
20 to 40 min; 45 min for systems with door-to-drug times
40 min; p  0.0001 for both). Similarly, EMS with field
management times longer than 20 min reduced their aver-
age time to initiation of reperfusion therapy by 30 min or
more with prehospital rPA (median time saved: 30 min for
systems with field times 20 to 30 min; 48 min for systems
with field times 30 min; p  0.0001 for both).
STRES. The success of reperfusion therapy was assessed
noninvasively by quantitative interpretation of the degree of
STRES on the 12-lead ECG. Of the 315 baseline ECGs
performed, 18 could not be interpreted for STRES due to
insufficient ST deviation for quantitative determination; 5
had left bundle branch block or an accelerated idioventricu-
lar rhythm, and 6 were not available for submission to the
core laboratory. Evaluable ECGs from baseline and emer-
gency department arrival were received for 267 patients. At
hospital arrival, a median of 11 min (25th to75th percentile,
7 to 18 min) after the first bolus of rPA, 26.2% of patients
had 50% resolution of the sum of ST-segment deviation
at baseline. Complete (70%) STRES was observed in
13.5% of patients. A total of 237 had evaluable ECGs at
baseline and 90 min. By 90 min after the initial bolus of
rPA, 59.9% of patients were found to have 50% STRES,
with 49.4% achieving complete STRES. Expressed as a
continuous variable, the median STRES observed at 90 min
after rPA was 67.7% (25th to75th, 23.9% to 86.6%). When
compared with data regarding STRES from prior in-
hospital fibrinolytic trials interpreted by our core laboratory
(17,18), similar rates of complete ST resolution (50%)
were achieved 90 min after fibrinolysis. However, patients
treated with prehospital rPA achieved this degree of
STRES approximately 30 min earlier relative to first med-
ical contact with the patient (Fig. 2).
Clinical outcomes. Complete data regarding clinical out-
comes were available for 301 patients. Through hospital
discharge or day 7, there were 14 (4.7%, exact 95% confi-
dence interval [CI] 2.6% to 7.7%) deaths. Five (1.7%, exact
95% CI 0.5% to 3.8%) patients had major bleeding events
other than intracranial hemorrhage, and three patients
(1.0%, exact 95% CI 0.2% to 2.9%) suffered intracranial
bleeding. These rates are placed in the context of recent
in-hospital research experience with rPA in Table 3 (19).
Sixty-five (21%) patients underwent diagnostic coronary
angiography, and 56 had a percutaneous intervention per-
formed within 6 h (median 2.4 h) after presentation. With
the exception of four patients, all had received both doses of
rPA. Among those patients undergoing coronary interven-
tion, there was one major bleeding event and no intracranial
hemorrhages. Twenty-four patients were treated with an
adjunctive glycoprotein IIb/IIIa inhibitor (all abciximab).
Procedural success as indicated by the operator was achieved
in 93% of cases.
DISCUSSION
We found that with a straightforward training program
paramedical personnel can act in conjunction with a medical
control physician to effectively screen patients with sus-
pected acute MI and rapidly initiate treatment with rPA for
fibrinolytic-eligible patients with STEMI. Moreover, in a
geographically diverse set of emergency medical systems
with a large urban representation and door-to-drug times
typical of the current experience in North America, admin-
istration of prehospital rPA reduced the time to reperfusion
therapy by approximately 30 min, compared with historical
performance, and resulted in a 10-fold increase in the
proportion of patients treated within 30 min after first
medical contact. In addition, our findings regarding STRES
provide supportive evidence that the time to successful
reperfusion was reduced among patients treated with pre-
hospital fibrinolytic. These data extend upon prior work
conducted in predominantly rural areas, single highly expe-
rienced emergency medical systems and in European centers
where mobile intensive care unit teams usually include a
Figure 1. Cumulative distribution of time to initiation of fibrinolytic from
emergency medical service (EMS) arrival for patients treated with prehos-
pital reteplase (rPA) versus in-hospital fibrinolytic. ER TIMI 19  Early
Retavase Thrombolysis In Myocardial Infarction 19 trial.
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supervising physician (5–10). Our findings regarding the
feasibility of and time savings with prehospital administra-
tion of rPA are likely to be applicable to a broad range of
emergency medical systems in North America.
Our observations from ER-TIMI 19 are also likely to be
relevant to the use of other bolus-dosed fibrinolytics (20),
such as tenecteplase, which is undergoing evaluation for
prehospital use in an ongoing multicenter trial. Neverthe-
less, by virtue of its double bolus regimen, rPA may offer
greater flexibility with respect to options for further care
upon arrival in the emergency department than single bolus
agents; for example, omission of the second bolus may
reduce bleeding risk in patients referred for immediate
coronary intervention. However, the potential clinical ad-
vantages of alternative strategies after single 10 U bolus
dosing of rPA have not been evaluated in clinical trials.
Rationale for prehospital fibrinolysis. Experimental data
from animal models have provided direct evidence of the
critical relation between duration of arterial occlusion and
the extent of irreversible myocardial injury (21–25). In the
open-chest anesthetized dog, at 40 min after the onset of
occlusion, 55% of the myocardium at risk remains viable,
whereas by 180 min, only one-third of the jeopardized
territory is salvageable (21). Data from multiple clinical
studies since have supported the clinical relevance of such
experimental observations, documenting a relation between
time to the initiation of reperfusion therapy and survival
among patients with STEMI (1,3,26–28). Particularly in
the first 2 h after symptom onset, relatively small delays in
treatment carry substantial implications for clinical out-
comes (1,4). For example, based on a meta-analysis per-
formed by Boersma et al. (4), treatment 30 min earlier in the
first 90 min after symptom onset results in an additional 10
to 30 lives saved per thousand treated. In addition, among
patients with STEMI randomized to prehospital versus
Figure 2. Proportion of patients with complete (70%) ST-segment resolution (STRES) plotted by time from emergency medical service (EMS) arrival.
Time to treatment data are from Early Retavase-Thrombolysis In Myocardial Infarction 19 (ER-TIMI 19) trial patients treated with reteplase (rPA) and
historical controls. ST-segment resolution data for patients treated with in-hospital fibrinolytic are from prior TIMI trials interpreted by the TIMI
Electrocardiogram Core Laboratory, Boston, Massachusetts (17,18). ED  emergency department.
Table 3. In-Hospital Events
Prehospital rPA
Events (%)
In-Hospital rPA*
Events (%)
Death 4.7 4.5
Reinfarction 3.3 3.5
Cardiogenic shock 7.3 9.4†
Major hemorrhage 1.7‡ 2.3§
Intracranial hemorrhage 1.0 0.6
Nonhemorrhagic stroke 1.0 0.3
*Data from Global Utilization of Strategies to Open Occluded Arteries (GUSTO)-V,
patients treated with full dose reteplase (19); †Hypotension requiring treatment;
‡Thrombolysis In Myocardial Infarction classification major hemorrhage, other than
intracranial; §GUSTO-defined severe  moderate bleeding, excluding intracranial.
rPA  reteplase.
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in-hospital initiation of alteplase in the Myocardial Infarc-
tion Triage and Intervention (MITI) trial, those treated
within the first 70 min after symptom onset had better left
ventricular function and improved survival (8). Notably, the
prehospital strategy in MITI increased the proportion of
patients treated within that window by approximately four-
to five-fold.
Together, such experimental and clinical data provide a
highly consistent body of evidence supporting a rationale for
treatment as soon as possible after identifying the patient
with indications for fibrinolysis. Advances in technology
have now made rapid evaluation of the patient with sus-
pected myocardial ischemia possible in the field (13,29,30).
Performance of prehospital 12-lead ECGs has been shown
to reduce time to treatment and perhaps improve survival
among patients with STEMI (31). Consistent with our
findings, others have shown that paramedical personnel
using prehospital electrocardiography and standardized
checklists while in communication with a medical control
physician can rapidly identify fibrinolytic-eligible patients
with accuracy equivalent to that achieved in the emergency
department (32–35). Such progress has reinforced the no-
tion that the continuum of emergency cardiac care begins at
the first medical contact with the patient, and opened the
opportunity for rapid identification and earlier treatment of
patients with STEMI.
Clinical implications. No single study has provided suffi-
ciently compelling evidence to promote widespread use of
prehospital fibrinolysis in North America. However, when
considered in the context of previous studies, the results of
ER-TIMI 19 support consideration of prehospital fibrino-
lytic programs for a broad base of emergency medical
systems. Consistent findings across multiple trials demon-
strate a time savings with prehospital fibrinolysis, ranging
between 33 to 130 min, depending upon the setting (11).
Meta-analysis of six randomized trials indicates a 17%
reduction in the odds of death with prehospital compared
with in-hospital initiation of fibrinolysis and shows no
impact of whether the on-scene evaluation is conducted by
a physician versus paramedical personnel (11). Such benefit
appears to come without any detectable difference in the risk
of major bleeding or adverse cardiovascular events with
prehospital therapy (8,10). Our findings in ER-TIMI 19
demonstrate that, even with continued progress in the
reduction of door-to-drug times, a prehospital fibrinolytic
program saves time if either field management or door-to-
drug times exceed 20 min. Thus, in light of the compelling
rationale for treatment as early as possible and evidence that
fibrinolysis can be targeted accurately and safely in the field,
it appears that if the necessary infrastructure to support
prehospital fibrinolysis is in place, there is little reason to
delay treatment even if the temporal gains for any one
patient may be modest.
Study limitations. Our analysis of the time saved by
prehospital fibrinolysis is based on comparison of the
experimental group to historical controls rather than a
randomized concurrent comparison. As the entry criteria for
ER-TIMI 19 mirrored standard guidelines for determina-
tion of eligibility for fibrinolysis (36) in place before initia-
tion of ER-TIMI 19, and were applied by the same medical
control physicians, we expect that any differences in patient
selection between patients enrolled in ER-TIMI 19 and the
historical controls were likely to be small. Nevertheless,
intrinsic to the design of trials involving comparison to
historical controls, variations in patient selection may exist.
Thus, although the control population was drawn from the
same EMS participating in ER-TIMI 19, the possibility of
heterogeneity of the patient populations and ascertainment
of the treatment times remains. In addition, many of the
systems participating in ER-TIMI 19 were not routinely
performing prehospital electrocardiography before starting
the trial. It is not possible on the basis of the data collected
in ER-TIMI 19 to determine the amount of time that
might have been saved in these systems by introducing
performance of prehospital ECGs alone, without prehospi-
tal administration of the fibrinolytic. The results of ER-
TIMI 19 do, however, demonstrate the overall time saved
with introduction of a prehospital fibrinolytic program,
including accurate patient identification and administration
of rPA, compared with current practice in a group of
emergency medical systems with diverse experience. Our
findings may not be immediately relevant to centers where
the primary mode of reperfusion therapy is direct percuta-
neous coronary intervention. However, the majority of
medical centers in North America are not able to provide
round-the-clock access to rapid primary angioplasty and,
thus, pharmacologic therapy remains the primary mode of
therapy for STEMI. Moreover, as upstream administration
of a reduced dose of fibrinolytic alone or in combination
with a platelet glycoprotein IIb/IIIa receptor antagonist
continues to undergo study as a potential facilitator of direct
angioplasty (37), it is possible that prehospital initiation of
reperfusion therapy may become a desirable component of
strategies for immediate percutaneous revascularization in
STEMI.
Conclusions. A prehospital strategy of electrocardiogra-
phy, confirmation of fibrinolytic eligibility and administra-
tion of rPA is a feasible approach to accelerating the time to
reperfusion in patients with STEMI. Valuable time savings
can be achieved even in the setting of contemporary trans-
port and door-to-drug times and may translate to improved
outcomes for patients treated with prehospital fibrinolysis.
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